| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Barney S. Graham | Q89108863 |
| P2860 | cites work | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 |
| Determinants of early life immune responses to RSV infection | Q26764790 | ||
| Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. | Q30425776 | ||
| Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. | Q33840469 | ||
| Community respiratory viruses: organ transplant recipients | Q33950817 | ||
| Risk of primary infection and reinfection with respiratory syncytial virus | Q34188122 | ||
| Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
| Immunity to RSV in Early-Life. | Q34264615 | ||
| Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group | Q34307413 | ||
| Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology | Q34364942 | ||
| Respiratory syncytial virus infection in elderly and high-risk adults | Q34414401 | ||
| Antiviral B cell and T cell immunity in the lungs. | Q34454614 | ||
| A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation | Q34547769 | ||
| Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma | Q35097216 | ||
| A Numerically Subdominant CD8 T Cell Response to Matrix Protein of Respiratory Syncytial Virus Controls Infection with Limited Immunopathology | Q35946229 | ||
| Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. | Q35973617 | ||
| Nonviral delivery of self-amplifying RNA vaccines | Q36221799 | ||
| Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera | Q36353767 | ||
| Human genetic factors and respiratory syncytial virus disease severity | Q36943137 | ||
| The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes | Q36994686 | ||
| Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. | Q37293748 | ||
| Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. | Q37347267 | ||
| The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines | Q37384009 | ||
| Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. | Q37442017 | ||
| Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors | Q37593886 | ||
| Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults | Q37669850 | ||
| Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation | Q37690464 | ||
| Respiratory syncytial virus mechanisms to interfere with type 1 interferons | Q38173281 | ||
| The histopathology of fatal untreated human respiratory syncytial virus infection | Q38435017 | ||
| Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. | Q38699466 | ||
| Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older | Q39392164 | ||
| Nucleoside Modified mRNA Vaccines for Infectious Diseases | Q40405926 | ||
| A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. | Q40922844 | ||
| Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial | Q40933391 | ||
| Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats | Q41026321 | ||
| Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections | Q41055844 | ||
| Consequences of immature and senescent immune responses for infection with respiratory syncytial virus | Q42247610 | ||
| Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals | Q44480572 | ||
| A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. | Q45382330 | ||
| Primary virus pneumonitis in infants. | Q45389729 | ||
| Respiratory syncytial virus infection in Navajo and White Mountain Apache children | Q45731441 | ||
| Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group | Q45749177 | ||
| Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndrome | Q45828778 | ||
| Immunity to and frequency of reinfection with respiratory syncytial virus | Q45853042 | ||
| An aged mouse model for RSV infection and diminished CD8(+) CTL responses. | Q51729329 | ||
| Recovery of cytopathogenic agent from chimpanzees with coryza | Q74223084 | ||
| Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group | Q77300551 | ||
| P304 | page(s) | 107-112 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Current opinion in virology | Q26842394 |
| P1476 | title | Vaccine development for respiratory syncytial virus | |
| P478 | volume | 23 |
| Q101126113 | A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults |
| Q52607180 | A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study. |
| Q95326762 | A gammaherpesvirus licenses CD8 T cells to protect the host from pneumovirus-induced immunopathologies |
| Q90084004 | A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein |
| Q90201371 | Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles |
| Q47562812 | Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts |
| Q56967587 | Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States |
| Q64108972 | Epitope-Specific Serological Assays for RSV: Conformation Matters |
| Q57067581 | Evolution of Human Respiratory Syncytial Virus (RSV) over Multiple Seasons in New South Wales, Australia |
| Q59359632 | Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches |
| Q49361412 | Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation |
| Q60954877 | Innate Immune Cell Suppression and the Link With Secondary Lung Bacterial Pneumonia |
| Q96302969 | Master manipulators: how herpesviruses alter immune responses to RSV |
| Q83231499 | Molecular organization and dynamics of the fusion protein Gc at the hantavirus surface |
| Q92083068 | Mutation of Respiratory Syncytial Virus G Protein's CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells |
| Q52579157 | Neonatal Immunization: Rationale, Current State, and Future Prospects. |
| Q92069304 | New technologies and applications in infant B cell immunology |
| Q89993503 | Original Antigenic Sin and Respiratory Syncytial Virus Vaccines |
| Q91782516 | Peptide Antiviral Strategies as an Alternative to Treat Lower Respiratory Viral Infections |
| Q64278393 | Phospholipid regulation of innate immunity and respiratory viral infection |
| Q47210194 | Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference |
| Q64264210 | Prevention of Pediatric Respiratory Syncytial Virus Lower Respiratory Tract Illness: Perspectives for the Next Decade |
| Q38694691 | Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during an early stage of infection. |
| Q91361642 | Respiratory syncytial virus entry and how to block it |
| Q64118246 | Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity |
| Q41922224 | Role of viral infections in the development and exacerbation of asthma in children |
| Q115694868 | Roles of Human Respiratory Syncytial Virus Proteins in Immune Responses |
| Q90147842 | Selection of adjuvants for vaccines targeting specific pathogens |
| Q111368077 | Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern |
| Q64117055 | Systematic comparison of respiratory syncytial virus-induced memory B cell responses in two anatomical compartments |
| Q90685670 | The Journey to an RSV Vaccine |
| Q59358526 | The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates |
| Q64229661 | Utility of the Neonatal Calf Model for Testing Vaccines and Intervention Strategies for Use against Human RSV Infection |
| Q64129570 | siRNA-Mediated Simultaneous Regulation of the Cellular Innate Immune Response and Human Respiratory Syncytial Virus Replication. |
Search more.